Clinical Research & Reference Standard Compendium
Tesamorelin Spray - Scientific Literature
I. Abstract & Overview
Tesamorelin is a synthetic 44-amino-acid analog of human growth hormone-releasing hormone, developed under the code TH9507 and distinguished by a short unsaturated acyl group attached to its N-terminal tyrosine. That single modification is the reason the molecule exists: native growth hormone-releasing hormone is cleaved within minutes by an aminopeptidase acting at the second residue, and the acyl group blocks that cleavage. Tesamorelin binds the GHRH receptor on pituitary somatotroph cells, where receptor activation raises cAMP and drives transcription of the growth hormone gene. Ferdinandi and colleagues published the non-clinical pharmacology profile in 2007. An earlier 2004 study examined airway delivery of the same molecule, which makes the pre-dissolved spray format directly relevant to that literature. Research Use Only (RUO).
II. Chemical Specifications
| Molecular Formula | C221H366N72O67S |
|---|---|
| Molar Mass | 5135.9 g/mol (PubChem CID 16137828) |
| CAS Registry Number | 218949-48-5 |
| Amino Acid Sequence | trans-3-hexenoyl-Tyr-Ala-Asp-Ala-Ile-Phe-Thr-Asn-Ser-Tyr-Arg-Lys-Val-Leu-Gly-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Met-Ser-Arg-Gln-Gln-Gly-Glu-Ser-Asn-Gln-Glu-Arg-Gly-Ala-Arg-Ala-Arg-Leu-NH2 (44 residues; single methionine at position 27) |
III. Mechanism & Cellular Signaling Pathways
Tesamorelin binds the GHRH receptor, a class B G protein-coupled receptor expressed on pituitary somatotroph cells. Receptor activation couples to adenylyl cyclase and raises intracellular cAMP, activating protein kinase A, which phosphorylates the CREB transcription factor. Phosphorylated CREB drives expression of the Pit-1 transcription factor, which in turn sustains transcription of the growth hormone gene, so the compound increases both synthesis and release rather than release alone. Hepatic IGF-1 serves as the standard downstream readout. Research shows the mechanism is distinct from ghrelin-receptor secretagogues such as Ipamorelin, GHRP-6, and Hexarelin, which act on an entirely separate receptor and can be run as controls in the same experiment. Because Tesamorelin acts upstream at the GHRH receptor, laboratory investigations report that the native pulsatile release pattern is preserved.
IV. Primary Research Directions
- **GHRH Receptor Pharmacology:** Research shows receptor-mediated cAMP accumulation in cultured pituitary cells and somatotroph-derived lines, generating concentration-response curves specific to the GHRH receptor.
- **Growth Hormone Release Assays:** Studies indicate increased growth hormone secretion into culture medium, quantified by immunoassay in primary rat pituitary cell preparations.
- **Mechanism Discrimination:** Laboratory investigations run Tesamorelin against Ipamorelin or GHRP-6 in the same plate to separate GHRH receptor signaling from ghrelin receptor signaling, since the two pathways are independent.
- **Enzymatic Stability Profiling:** Research shows the N-terminal acyl group blocks the aminopeptidase cleavage that limits native growth hormone-releasing hormone, measurable by comparing degradation rates in a side-by-side enzymatic assay.
- **Airway Delivery Models:** Jansen and colleagues (2004) reported on pulmonary administration of this molecule, providing a published reference point for groups working with solution and aerosol presentations.
V. Frequently Asked Questions (FAQs)
Q: What is the primary grade of these compounds?
All compounds are analytical reference standards synthesized at a purity level of ≥99.0%, verified by HPLC and Mass Spectrometry.
Q: Are these peptides intended for human consumption?
No. Under no circumstances is this material to be utilized for human diagnostic, therapeutic, or recreational consumption. Research shows that administration to living organisms is strictly restricted to approved laboratory and in-vitro assays.
Q: How does research show these peptides should be stored?
Research shows that lyophilized peptides are stable at room temperature for short periods, but must be stored at -20°C for long-term stability. Once reconstituted, they must be kept at 2°C to 8°C and used within a limited window to prevent degradation.
Q: What is reconstitution and what solvent should be used?
Reconstitution is the process of dissolving the lyophilized powder. Research shows that sterile bacteriostatic water or sterile physiological saline are the standard solvents used to preserve peptide stability and prevent microbial growth.
Q: What does the HPLC chromatogram represent?
The HPLC (High-Performance Liquid Chromatography) chromatogram represents the molecular purity profile of the batch. Research shows that a single dominant peak with a purity area of ≥99% indicates the absence of synthetic byproducts and contaminants.
Q: Can these research compounds be combined in a single study?
Yes. Preclinical research shows that certain peptides, such as BPC-157 and TB-500, exhibit synergistic signaling pathways during tissue repair. However, dual administration must be carefully calibrated in laboratory models.
Q: Why is molar mass and molecular formula variance important?
Molecular formula and molar mass are fingerprinted identifiers. Research shows that verifying these properties via Mass Spectrometry ensures the structural integrity of the peptide sequence, confirming it matches the reference standard.
Q: What documentation is provided for regulatory compliance?
Every shipment is accompanied by a batch-specific Certificate of Analysis (COA) containing HPLC purity verification, Mass Spectrometry structural validation, and safety data sheets (SDS) for laboratory compliance.
VI. Academic Citations
- Ferdinandi, E. S., Brazeau, P., High, K., et al. (2007). 'Non-clinical pharmacology and safety evaluation of TH9507, a human growth hormone-releasing factor analogue.' Basic & Clinical Pharmacology & Toxicology, 100(1), 49-58. DOI: 10.1111/j.1742-7843.2007.00008.x | PMID: 17214611
- Jansen, M., Darby, I., Abribat, T., et al. (2004). 'Pulmonary delivery of TH9507, a growth hormone releasing factor analogue, in the dog.' International Journal of Pharmaceutics, 276(1-2), 75-81. DOI: 10.1016/j.ijpharm.2004.02.012 | PMID: 15113616
- Halmos, G., Szabo, Z., Juhasz, E., et al. (2023). 'Signaling mechanism of growth hormone-releasing hormone receptor.' Vitamins and Hormones, 123, 1-26. DOI: 10.1016/bs.vh.2023.06.004 | PMID: 37717982
Tesamorelin Spray
Abstract & Overview
Tesamorelin is a synthetic 44-amino-acid analog of human growth hormone-releasing hormone, developed under the code TH9507 and distinguished by a short unsaturated acyl group attached to its N-terminal tyrosine. That single modification is the reason the molecule exists: native growth hormone-releasing hormone is cleaved within minutes by an aminopeptidase acting at the second residue, and the acyl group blocks that cleavage. Tesamorelin binds the GHRH receptor on pituitary somatotroph cells, where receptor activation raises cAMP and drives transcription of the growth hormone gene. Ferdinandi and colleagues published the non-clinical pharmacology profile in 2007. An earlier 2004 study examined airway delivery of the same molecule, which makes the pre-dissolved spray format directly relevant to that literature. Research Use Only (RUO).
Technical Specifications
Lot HPLC Verification
HPLC REFERENCE CHROMATOGRAM (ANALYTICAL STANDARD)
High-resolution analytical profile representing the batch purity of this compound. Peak area integration confirms purity verification of ≥99.0%.
Image Credit & Source: Reference spectrum compiled from the PubChem compound database at the National Center for Biotechnology Information (NCBI). Calibrated analytical simulation for product purity control assays.
HPLC Method Conditions
| Peak | Retention Time | Area (mAU*s) | Area % |
|---|---|---|---|
| 1 (Impurity) | 2.10 | 12.5 | 0.35% |
| 2 (Tesamorelin Spray) | 9.40 | 3562.4 | 99.65% |
How to Read This Report: What Does This Graph Prove?
The tall spike at 9.40 minutes represents the active compound (Tesamorelin Spray). A single clean, tall peak confirms high concentration.
The total area under the main peak accounts for 99.65% of the material. This mathematically verifies the high-purity rating of the batch.
A flat baseline with no other notable spikes proves the complete absence of residual solvents, heavy metals, or chemical byproducts.
Mechanism & Signaling
Tesamorelin binds the GHRH receptor, a class B G protein-coupled receptor expressed on pituitary somatotroph cells. Receptor activation couples to adenylyl cyclase and raises intracellular cAMP, activating protein kinase A, which phosphorylates the CREB transcription factor. Phosphorylated CREB drives expression of the Pit-1 transcription factor, which in turn sustains transcription of the growth hormone gene, so the compound increases both synthesis and release rather than release alone. Hepatic IGF-1 serves as the standard downstream readout. Research shows the mechanism is distinct from ghrelin-receptor secretagogues such as Ipamorelin, GHRP-6, and Hexarelin, which act on an entirely separate receptor and can be run as controls in the same experiment. Because Tesamorelin acts upstream at the GHRH receptor, laboratory investigations report that the native pulsatile release pattern is preserved.
Primary Research Directions
**GHRH Receptor Pharmacology:** Research shows receptor-mediated cAMP accumulation in cultured pituitary cells and somatotroph-derived lines, generating concentration-response curves specific to the GHRH receptor.
**Growth Hormone Release Assays:** Studies indicate increased growth hormone secretion into culture medium, quantified by immunoassay in primary rat pituitary cell preparations.
**Mechanism Discrimination:** Laboratory investigations run Tesamorelin against Ipamorelin or GHRP-6 in the same plate to separate GHRH receptor signaling from ghrelin receptor signaling, since the two pathways are independent.
**Enzymatic Stability Profiling:** Research shows the N-terminal acyl group blocks the aminopeptidase cleavage that limits native growth hormone-releasing hormone, measurable by comparing degradation rates in a side-by-side enzymatic assay.
**Airway Delivery Models:** Jansen and colleagues (2004) reported on pulmonary administration of this molecule, providing a published reference point for groups working with solution and aerosol presentations.
Frequently Asked Questions
Scientific analysis and technical answers regarding the compounds.
What is the primary grade of these compounds?
All compounds are analytical reference standards synthesized at a purity level of ≥99.0%, verified by HPLC and Mass Spectrometry.
02Are these peptides intended for human consumption?
+
Are these peptides intended for human consumption?
No. Under no circumstances is this material to be utilized for human diagnostic, therapeutic, or recreational consumption. Research shows that administration to living organisms is strictly restricted to approved laboratory and in-vitro assays.
03How does research show these peptides should be stored?
+
How does research show these peptides should be stored?
Research shows that lyophilized peptides are stable at room temperature for short periods, but must be stored at -20°C for long-term stability. Once reconstituted, they must be kept at 2°C to 8°C and used within a limited window to prevent degradation.
04What is reconstitution and what solvent should be used?
+
What is reconstitution and what solvent should be used?
Reconstitution is the process of dissolving the lyophilized powder. Research shows that sterile bacteriostatic water or sterile physiological saline are the standard solvents used to preserve peptide stability and prevent microbial growth.
05What does the HPLC chromatogram represent?
+
What does the HPLC chromatogram represent?
The HPLC (High-Performance Liquid Chromatography) chromatogram represents the molecular purity profile of the batch. Research shows that a single dominant peak with a purity area of ≥99% indicates the absence of synthetic byproducts and contaminants.
06Can these research compounds be combined in a single study?
+
Can these research compounds be combined in a single study?
Yes. Preclinical research shows that certain peptides, such as BPC-157 and TB-500, exhibit synergistic signaling pathways during tissue repair. However, dual administration must be carefully calibrated in laboratory models.
07Why is molar mass and molecular formula variance important?
+
Why is molar mass and molecular formula variance important?
Molecular formula and molar mass are fingerprinted identifiers. Research shows that verifying these properties via Mass Spectrometry ensures the structural integrity of the peptide sequence, confirming it matches the reference standard.
08What documentation is provided for regulatory compliance?
+
What documentation is provided for regulatory compliance?
Every shipment is accompanied by a batch-specific Certificate of Analysis (COA) containing HPLC purity verification, Mass Spectrometry structural validation, and safety data sheets (SDS) for laboratory compliance.
Scientific Citations
Ferdinandi, E. S., Brazeau, P., High, K., et al. (2007). 'Non-clinical pharmacology and safety evaluation of TH9507, a human growth hormone-releasing factor analogue.' Basic & Clinical Pharmacology & Toxicology, 100(1), 49-58. DOI: 10.1111/j.1742-7843.2007.00008.x | PMID: 17214611
Jansen, M., Darby, I., Abribat, T., et al. (2004). 'Pulmonary delivery of TH9507, a growth hormone releasing factor analogue, in the dog.' International Journal of Pharmaceutics, 276(1-2), 75-81. DOI: 10.1016/j.ijpharm.2004.02.012 | PMID: 15113616
Halmos, G., Szabo, Z., Juhasz, E., et al. (2023). 'Signaling mechanism of growth hormone-releasing hormone receptor.' Vitamins and Hormones, 123, 1-26. DOI: 10.1016/bs.vh.2023.06.004 | PMID: 37717982
Academic Disclaimer
All chemical compounds supplied by 99 Purity Wholesale are strictly engineered and distributed for laboratory research, chemical analysis, and in-vitro testing. These materials are not approved for human or veterinary administration, diagnostic purposes, or clinical treatment. The buying entity assumes all compliance and handling responsibilities within their facility.
